glp-1 versus glp-2 Drugs and Type 1 Diabetes: Less Insulin, Better Time in Range — What the Evidence GLP-1 vs. GLP-2 vs. GLP-3:

Renal function should also be considered when interpreting retatrutide dosage data

Similar content being viewed by others Introduction Adverse cardiometabolic outcomes, encompassing hypertension, metabolic syndrome (MetS), nonalcoholic fatty liver disease (NAFLD), type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular diseases (CVDs), represent a significant public health burden globally

Although these side effects are common, they can often be managed without discontinuation of the medication [15,74]

Epub 2025 Jan 23 Ethics declarations Conflict of interest Both authors declare that they have no conflict of interest with regard to the publication of this manuscript

Biologic Versus Non-Biologic Immunosuppressant Use and Outcomes After ORIF of Closed Ankle Fractures: A Propensity-Matched Analysis McKenna W